Release Date: Tuesday, July 18, 2017    

Expiration Date: Wednesday, July 18, 2018

Educational Overview
Antimicrobial resistance is a critical public health and safety dilemma. Over the past few years, we have witnessed an inexorable increase in the number of infections due to resistant pathogens, including ESBL-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae (CRE), multidrug-resistant (MDR) Pseudomonas and Acinetobacter. As a result of this crisis, several national initiatives were implemented to combat bacterial resistance. Addressing the issue of antimicrobial resistance requires a multifaceted approach that involves limiting inappropriate use or overuse of antimicrobials (e.g., following principles of antimicrobial stewardship), surveillance of resistance, rapid diagnostics to identify resistant infections, optimized use of current agents, and development of newer, more effective agents. It is the responsibility of all healthcare providers to contribute efforts in minimizing the development and spread of resistant pathogens.

Target Audience
Addressing the challenges of MDR bacteria requires an interprofessional approach that includes all healthcare providers involved in the prevention, diagnosis, and management of patients with or at risk for these infections. Therefore, this continuing medical education activity will target a variety of healthcare providers that include ID physicians, infection control specialists, hospital epidemiologists, hospitalists, clinical microbiologists, nurses, and clinical pharmacists.

Learning Objectives
Upon completing this activity, participants will be able to:

  • Discuss current epidemiological trends regarding multidrug-resistant (MDR) Gram-negative bacteria and their impact on clinical outcomes
  • Summarize approaches aimed at minimizing the spread and development of antimicrobial resistance, including antimicrobial stewardship strategies and rapid diagnostic assays
  • Evaluate the potential role of new and emerging antimicrobial agents as part of the treatment armamentarium when treating infections caused by MDR Gram-negative bacteria

Educational Format

This Webcast on Demand is based on the Satellite Symposium presented at ASM Microbe in New Orleans, LA on Saturday, June 3, 2017.

The Webcast on Demand includes the following topics:       

MDR Crisis: The Challenge of the Modern Era

Understanding the Current MDR Landscape

Advanced Tools to Address the Crisis

New and Emerging Antimicrobial Agents

Open Forum: Q and A

Note: If you have received credit for attending the live program by the same name, you are not eligible to apply for credit for this online version.



Keith A. Rodvold, PharmD, FCCP, FIDSA

Professor of Pharmacy Practice and Medicine
Colleges of Pharmacy and Medicine
University of Illinois at Chicago
Chicago, IL





AccreditationCenter for Independent Healthcare Education is accredited by the Accreditation Council for Pharmacy Education as a provider for continuing pharmacy education. Center has assigned 1.0 contact hour (0.1 CEUs) of continuing pharmacy education credits for participating in this activity.

 ACPE UAN: 0473-9999-17-009-H01-P
Activity type: Knowledge-based


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the Center for Independent Healthcare Education and Vemco MedEd, LLC. Center for Independent Healthcare Education (Center) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Center for Independent Healthcare Education designates this Enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For questions regarding the accreditation of this activity, please contact us at


Method of Participation and Instruction for Credit

  1. Review the entire CE information including target audience, learning objectives, and disclosures.
  2. Review the activity.
  3. Complete the Post Test, Evaluation, and Credit Application Form.
  4. Please note that to receive credit you must achieve a score of at least 70%.
  5. Pharmacists: The information that you participated will be uploaded to CPEMonitor and you will be able to access your credits from the profile you set up with NABP. For more information, please visit
  6. Physicians: Certificate of Credit will be emailed within 4 weeks of successful completion of the activity.


Disclosure of Conflicts of Interest
In accordance with policies set forth by the Accreditation Council for Continuing Medical Education (ACCME), Center for Independent Healthcare Education requires all faculty members and spouses/significant others with an opportunity to affect the content of a continuing education activity to disclose any relevant financial relationships during the past 12 months with commercial interests. A commercial interest is any entity producing, marketing, reselling or distributing health care goods or services consumed by or used on patients. Relationships with commercial interests and conflicts of interest resulting from those relationships must be revealed to the audience and resolved prior to the activity.

Relevant relationships include roles such as speaker, author, consultant, independent contractor (including research), employee, investor, advisory committee member, board member, review panelist, and investigator. If a potential speaker or author indicates a possible conflict of interest, the conflict will be resolved by choosing another speaker or author for that topical area, or the slides, handouts, and/or monograph will be reviewed and approved by a qualified commercially-disinterested peer.



Keith A. Rodvold, PharmD has relevant financial relationships with the following commercial interests:
            Advisory Board: Achaogen, Bayer, The Medicines Company, Motif, Nabriva, Paratek, Shionogi, Theravance, Melinta, GlaxoSmithKlein, Spero Therapeutics
            Research Support: Allergan, Theravance
            Speakers Bureau: Merck & Co., Inc. and The Medicines Company
Dr. Rodvold discusses the off-label uses of the following: Ceftazidime-Avibactam; Ceftolozane-Tazobactam; Meropenem-Vaborbactam; Imipenem-Relebactam; Plazomicin; IV Fosfomycin; Eravacycline; Cefiderocol; Amikacin Inhale (BAY41-6551)

No other speakers, authors, planners or content reviewers have any relevant financial relationships to disclose.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.

There is no fee to participate in this activity.

Hardware/Software Requirements
Microsoft Internet Explorer, Mozilla Firefox, Apple Safari or Google Chrome with the QuickTime Plug-in
Note: Please disable any “pop-up blocker” features.

Adobe® Reader version 7 or above to view PDF files (If you do not have Adobe® Reader, you can download it for free from
Adobe Flash Player version 10 or above to view multimedia content (If you do
not have Adobe Flash Player, you can download it for free from

Connection Speed
Cable, DSL, or better of at least 300 kbps

System Check
Please e-mail any questions or concerns to

Copyright Statement
Copyright © 2017 Vemco MedEd, LLC. All Rights Reserved. Permission for accreditation use granted to Center for Independent Healthcare Education.

Privacy Policy

Joint Providership
This activity is jointly provided by Center for Independent Healthcare Education and Vemco MedEd.

Commercial Support

This activity is supported by educational grants from
The Medicines Company and Merck & Co., Inc.


By clicking here, I acknowledge that
I have read the entire CE information.